Cargando…
Exometabolom analysis of breast cancer cell lines: Metabolic signature
Cancer cells show characteristic effects on cellular turnover and DNA/RNA modifications leading to elevated levels of excreted modified nucleosides. We investigated the molecular signature of different subtypes of breast cancer cell lines and the breast epithelial cell line MCF-10A. Prepurification...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4544000/ https://www.ncbi.nlm.nih.gov/pubmed/26293811 http://dx.doi.org/10.1038/srep13374 |
_version_ | 1782386634245799936 |
---|---|
author | Willmann, Lucas Erbes, Thalia Halbach, Sebastian Brummer, Tilman Jäger, Markus Hirschfeld, Marc Fehm, Tanja Neubauer, Hans Stickeler, Elmar Kammerer, Bernd |
author_facet | Willmann, Lucas Erbes, Thalia Halbach, Sebastian Brummer, Tilman Jäger, Markus Hirschfeld, Marc Fehm, Tanja Neubauer, Hans Stickeler, Elmar Kammerer, Bernd |
author_sort | Willmann, Lucas |
collection | PubMed |
description | Cancer cells show characteristic effects on cellular turnover and DNA/RNA modifications leading to elevated levels of excreted modified nucleosides. We investigated the molecular signature of different subtypes of breast cancer cell lines and the breast epithelial cell line MCF-10A. Prepurification of cell culture supernatants was performed by cis-diol specific affinity chromatography using boronate-derivatized polyacrylamide gel. Samples were analyzed by application of reversed phase chromatography coupled to a triple quadrupole mass spectrometer. Collectively, we determined 23 compounds from RNA metabolism, two from purine metabolism, five from polyamine/methionine cycle, one from histidine metabolism and two from nicotinate and nicotinamide metabolism. We observed major differences of metabolite excretion pattern between the breast cancer cell lines and MCF-10A, just as well as between the different breast cancer cell lines themselves. Differences in metabolite excretion resulting from cancerous metabolism can be integrated into altered processes on the cellular level. Modified nucleosides have great potential as biomarkers in due consideration of the heterogeneity of breast cancer that is reflected by the different molecular subtypes of breast cancer. Our data suggests that the metabolic signature of breast cancer cell lines might be a more subtype-specific tool to predict breast cancer, rather than a universal approach. |
format | Online Article Text |
id | pubmed-4544000 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-45440002015-09-01 Exometabolom analysis of breast cancer cell lines: Metabolic signature Willmann, Lucas Erbes, Thalia Halbach, Sebastian Brummer, Tilman Jäger, Markus Hirschfeld, Marc Fehm, Tanja Neubauer, Hans Stickeler, Elmar Kammerer, Bernd Sci Rep Article Cancer cells show characteristic effects on cellular turnover and DNA/RNA modifications leading to elevated levels of excreted modified nucleosides. We investigated the molecular signature of different subtypes of breast cancer cell lines and the breast epithelial cell line MCF-10A. Prepurification of cell culture supernatants was performed by cis-diol specific affinity chromatography using boronate-derivatized polyacrylamide gel. Samples were analyzed by application of reversed phase chromatography coupled to a triple quadrupole mass spectrometer. Collectively, we determined 23 compounds from RNA metabolism, two from purine metabolism, five from polyamine/methionine cycle, one from histidine metabolism and two from nicotinate and nicotinamide metabolism. We observed major differences of metabolite excretion pattern between the breast cancer cell lines and MCF-10A, just as well as between the different breast cancer cell lines themselves. Differences in metabolite excretion resulting from cancerous metabolism can be integrated into altered processes on the cellular level. Modified nucleosides have great potential as biomarkers in due consideration of the heterogeneity of breast cancer that is reflected by the different molecular subtypes of breast cancer. Our data suggests that the metabolic signature of breast cancer cell lines might be a more subtype-specific tool to predict breast cancer, rather than a universal approach. Nature Publishing Group 2015-08-21 /pmc/articles/PMC4544000/ /pubmed/26293811 http://dx.doi.org/10.1038/srep13374 Text en Copyright © 2015, Macmillan Publishers Limited http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Willmann, Lucas Erbes, Thalia Halbach, Sebastian Brummer, Tilman Jäger, Markus Hirschfeld, Marc Fehm, Tanja Neubauer, Hans Stickeler, Elmar Kammerer, Bernd Exometabolom analysis of breast cancer cell lines: Metabolic signature |
title | Exometabolom analysis of breast cancer cell lines: Metabolic signature |
title_full | Exometabolom analysis of breast cancer cell lines: Metabolic signature |
title_fullStr | Exometabolom analysis of breast cancer cell lines: Metabolic signature |
title_full_unstemmed | Exometabolom analysis of breast cancer cell lines: Metabolic signature |
title_short | Exometabolom analysis of breast cancer cell lines: Metabolic signature |
title_sort | exometabolom analysis of breast cancer cell lines: metabolic signature |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4544000/ https://www.ncbi.nlm.nih.gov/pubmed/26293811 http://dx.doi.org/10.1038/srep13374 |
work_keys_str_mv | AT willmannlucas exometabolomanalysisofbreastcancercelllinesmetabolicsignature AT erbesthalia exometabolomanalysisofbreastcancercelllinesmetabolicsignature AT halbachsebastian exometabolomanalysisofbreastcancercelllinesmetabolicsignature AT brummertilman exometabolomanalysisofbreastcancercelllinesmetabolicsignature AT jagermarkus exometabolomanalysisofbreastcancercelllinesmetabolicsignature AT hirschfeldmarc exometabolomanalysisofbreastcancercelllinesmetabolicsignature AT fehmtanja exometabolomanalysisofbreastcancercelllinesmetabolicsignature AT neubauerhans exometabolomanalysisofbreastcancercelllinesmetabolicsignature AT stickelerelmar exometabolomanalysisofbreastcancercelllinesmetabolicsignature AT kammererbernd exometabolomanalysisofbreastcancercelllinesmetabolicsignature |